Jimini Health Launches with $8M Seed Funding to Advance Mental Health Care
Stanford-based Jimini Health, a mental health startup founded in 2023, has announced its official launch with $8 million in seed funding from investors, including Zetta Venture Partners, LionBird, PsyMed, and BoxGroup. The company is developing a hybrid therapy model that combines licensed clinicians with AI-supported tools to provide tailored and continuous mental health care.
Jimini Health addresses limitations in traditional therapy—such as infrequent sessions—by integrating its AI assistant, Sage™, into care plans. Sage offers patients daily exercises and tools that reinforce therapeutic goals under the supervision of licensed therapists, ensuring clinical safety and personalized support. The funding will help Jimini enhance its AI capabilities, strengthen its safety systems, and scale operations to reach initial clients.
“Our mission is to integrate AI responsibly to support clinicians and improve continuity and quality of care,” said Luis Voloch, CEO and co-founder of Jimini Health.
How It Works: A Continuous Therapy Model
Jimini Health’s approach pairs expert therapists with technology to offer ongoing support:
- Personalized Matching: Patients are connected with licensed therapists who specialize in evidence-based approaches.
- Immediate Engagement: The Jimini app provides access to Sage, therapist messaging, and tools even before the first session.
- Virtual Sessions: Therapists use data from Sage during 50-minute sessions to guide care, while patients receive post-session recaps and actionable goals.
- 24/7 Support: Sage delivers tailored prompts and exercises between sessions, maintaining engagement and reinforcing progress.
This model addresses the gaps in traditional therapy by providing continuity of care and proactive daily support, which research shows significantly improves treatment outcomes. Unlike standalone AI tools, Sage works as part of a clinician-led system, ensuring therapy remains grounded in clinical rigor.
The company collaborates with researchers from Stanford, Harvard, and Yale to align its methods with the latest clinical science. Co-founders Luis Voloch, Mark Jacobstein, and Sahil Sud bring a range of experience in AI, healthcare, and biotechnology, shaping Jimini’s approach to therapy.
With its seed funding, Jimini plans to further develop its product, expand its client base, and refine its hybrid therapy model.
Topics: HealthTech
